Effect of aripiprazole augmentation of clozapine in schizophrenia: A double-blind, placebo-controlled study

Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: A systematic review and meta-analysis of randomized-controlled trials

“…Mainly, such improved view was caused by the more favorable outcomes observed in the latest study carried out by Muscatello and colleagues (Muscatello et al, 2011). While the data of this study might be the cause of data heterogeneity, it is of interest to note that this is the placebo-controlled, randomized trial with the longest study duration (24 weeks).…”

“…Four RCTs were short-term (8e24 weeks) comparison of aripiprazole and placebo in combination with clozapine (Chang et al, 2008;Fan et al, 2013;Fleischhacker et al, 2010;Muscatello et al, 2011) (see Table 1). The data of these four short-term RCTs (n ¼ 347) were quantitatively synthesized.…”

“…While four trials were 'double-blind' (Chang et al, 2008;Fan et al, 2013;Fleischhacker et al, 2010;Muscatello et al, 2011), the CHAT study applied an open-label design. No study had the problem of incomplete outcome data and selective reporting.…”

“…For the study of Muscatello et al (2011), the SDs of the BPRS, SAPS, and SANS change scores were imputed by using the changefrom-baseline SDs of another study (Chang et al, 2008) for computing the correlation coefficients. Table 1 The characteristics of five randomized, controlled trials of aripiprazole augmentation of clozapine in schizophrenic patients with clozapine-resistant or clozapine-related cardiometabolic risk.…”

Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study

“…Reviews and meta-analyses on APP all highlight the need for further and more conclusive RCTs Zink et al, 2010). Most positive findings stems from augmentation of clozapine, where some studies have shown efficacy in reducing positive symptoms (Muscatello et al, 2011;Shiloh et al, 1997), whereas others showed improving the metabolic burden from clozapine (Fleischhacker et al, 2010;Henderson et al, 2006). A meta-analysis by Taylor et al found only modest effects of combining another antipsychotic drug with clozapine (Taylor et al, 2012).…”